Skip to main content

Advertisement

SpringerLink
Log in

Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is a well-known risk factor for venous thromboembolism and cardiovascular (CV) disease development in the general population, but its role in thrombotic risk in essential thrombocythemia (ET) and polycythemia vera (PV) remains poorly understood. This retrospective multicenter study analyzed clinical correlations and the potential impact of CKD on thrombosis development in ET and PV patients. We included 167 patients (76 ET and 91 PV); 25.7% had CKD at diagnosis, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 for ≥ 3 months. Lower eGFR correlated with advanced age, female sex, higher granulocytes, higher serum C-reactive protein, history of thrombosis, CV risk factors, and the presence of palpable splenomegaly. CKD was univariately associated with inferior thrombosis-free survival in the entire cohort, as well as in both ET and PV patients. These results remained significant in the multivariate Cox regression models when adjusted to disease-specific risk models. Therefore, CKD could be a risk factor for thrombosis in ET and PV patients. Additional studies on a larger number of patients are needed to confirm our findings and to elucidate whether the addition of CKD to the current risk stratification models might improve prognostication in ET and PV patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferreira Cristina S, Polo B, Lacerda JF. Somatic mutations in Philadelphia chromosome-negative myeloproliferative neoplasms. Semin Hematol. 2018;55(4):215–22.

    Article  Google Scholar 

  2. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91:390–4.

    Article  Google Scholar 

  3. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133–43.

    Article  Google Scholar 

  4. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

    Article  Google Scholar 

  5. Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723–35.

    Article  Google Scholar 

  6. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19:135–40.

    Article  Google Scholar 

  7. Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. Chronic kidney disease and venous thromboembolism: a prospective study. Atherosclerosis Risk in Communities Study. Nephrol Dial Transplant. 2010;25:3296–301.

    Article  Google Scholar 

  8. Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91:797–807.

    Article  Google Scholar 

  9. Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18:2918–26.

    CAS  PubMed  Google Scholar 

  10. Provenzano M, Coppolino G, De Nicola L, Serra R, Garofalo C, Andreucci M, et al. Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol. 2019;7:314.

    Article  Google Scholar 

  11. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

    Article  Google Scholar 

  12. Kidney Disease Improving Global Outcomes Work Group. Chapter 4:Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl. 2013;3(1):91–111.

    Article  Google Scholar 

  13. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050–65.

    Article  CAS  Google Scholar 

  14. Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, et al. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica. 2019;104:e506–e509509.

    Article  Google Scholar 

  15. Christensen AS, Møller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38:490–5.

    Article  Google Scholar 

  16. Baek SW, Young Moon J, Ryu H, Choi YS, Song IK, Lee HY, et al. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. Korean J Intern Med. 2018;33:790–7.

    Article  CAS  Google Scholar 

  17. Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80:753–9.

    Article  Google Scholar 

  18. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  Google Scholar 

  19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.

    Article  CAS  Google Scholar 

  20. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49–61.

    Article  Google Scholar 

  21. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–25.

    Article  CAS  Google Scholar 

  22. Bailey GL, Katz AI, Hampers CL, Merrill JP. Alterations in serum enzymes in chronic renal failure. JAMA. 1970;28(213):2263–5.

    Article  Google Scholar 

  23. Nielsen VK, Kemp E, Laursen T. Lactic dehydrogenase in kidney tissue and renal disease. Adaptive change of the synthesis in acute failure. Acta Med Scand. 1968;184:109–19.

    Article  CAS  Google Scholar 

  24. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

    Article  CAS  Google Scholar 

  25. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.

    Article  CAS  Google Scholar 

  26. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611–6.

    Article  Google Scholar 

  27. Kim YK, Bae SY, Yu L, Kim NY, Lee SR, Ahn JS, et al. Renal adverse effect of anagrelide in patients with myeloproliferative neoplasms. Blood. 2011;118:5151.

    Article  Google Scholar 

  28. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Chronic Kidney Dis Prognosis Consort Lancet. 2010;375:2073–81.

    Google Scholar 

Download references

Acknowledgements

The authors would like to thank Antonija Redovniković, BA, for her help with language editing, and Marko Lucijanić, PhD, for his help in interpreting the data.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Šibenik-Knin County General Hospital, Stjepana Radića 83, 22000, Šibenik, Croatia

    Ivan Krečak & Velka Gverić-Krečak

  2. Department of Internal Medicine, Dr. Josip Benčević General Hospital, Slavonski Brod, Croatia

    Hrvoje Holik & Božena Coha

  3. School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia

    Hrvoje Holik

  4. Department of Internal Medicine, Zadar General Hospital, Zadar, Croatia

    Morić Perić Martina & Ivan Zekanović

Authors
  1. Ivan Krečak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hrvoje Holik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morić Perić Martina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivan Zekanović
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Božena Coha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Velka Gverić-Krečak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan Krečak.

Ethics declarations

Conflict of interest

The authors report no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krečak, I., Holik, H., Martina, M.P. et al. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol 112, 377–384 (2020). https://doi.org/10.1007/s12185-020-02898-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02898-7

Keywords

Search

Navigation